Keith J. Kendall, CEO and President at Aquestive Therapeutics, Inc. (AQST), bought 1,000 shares at $9.87 ($10K) on 2018-11-27, disclosed to the SEC on 2018-11-28.
Open-market purchase of $10k AQST by CEO and President. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Something here stands out, but not much.
| Filing → |
| AQST | BUY | 2018-11-26 | $80K | — | Filing → |